Special Issue

Advances in Phage Therapies

Message from the Guest Editor

Microorganisms invites researchers to contribute to a Special Issue dedicated to research advances in phage therapy, a promising approach to combating microbial infections.

We welcome original research, reviews, and communications covering various aspects of phage therapy. Topics of interest include phage discovery, characterization, engineering, and clinical applications. Studies elucidating phage–host interactions, viral replication, and evolution will provide insights into phage biology.

Furthermore, investigations into phage-based strategies for controlling bacterial pathogens, such as biofilm eradication, antimicrobial resistance mitigation, and targeted delivery systems, are highly encouraged. Research addressing safety, efficacy, and regulatory considerations will contribute to the translation of phage therapy into clinical practice.

By fostering interdisciplinary collaboration, this Special Issue aims to drive the development of novel phage-based therapies for personalized and targeted microbial control.

Guest Editor

Dr. Kovács Tamás
Department of Biotechnology, Nanophagetherapy Center, Enviroinvest Corporation, Kertváros u. 2., H-7632 Pécs, Hungary

Deadline for manuscript submissions

closed (15 January 2025)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/183474

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI